GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » EPS without NRI

Akili (AKLI) EPS without NRI : $-0.80 (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Akili EPS without NRI?

Akili's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.14. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.80.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Akili's EPS without NRI or its related term are showing as below:

AKLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -120.2   Med: -77.15   Max: -34.1
Current: -34.1

During the past 5 years, Akili's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -34.10% per year. The lowest was -120.20% per year. And the median was -77.15% per year.

AKLI's 3-Year EPS without NRI Growth Rate is ranked worse than
86.83% of 486 companies
in the Healthcare Providers & Services industry
Industry Median: 9.85 vs AKLI: -34.10

Akili's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

Akili's EPS (Basic) for the three months ended in Dec. 2023 was $-0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.


Akili EPS without NRI Historical Data

The historical data trend for Akili's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili EPS without NRI Chart

Akili Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-0.27 -0.33 -0.79 -2.83 -0.79

Akili Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.24 -0.19 -0.23 -0.14

Competitive Comparison of Akili's EPS without NRI

For the Health Information Services subindustry, Akili's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akili's PE Ratio without NRI Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Akili's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Akili's PE Ratio without NRI falls into.



Akili EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akili  (NAS:AKLI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Akili EPS without NRI Related Terms

Thank you for viewing the detailed overview of Akili's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Akili (AKLI) Business Description

Traded in Other Exchanges
Address
125 Broad Street, Fifth Floor, Boston, MA, USA, 02110
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
Executives
Jacqueline Studer officer: Chief Legal Officer IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin officer: See Remarks AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii director, officer: Chief Executive Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag officer: Chief Financial Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya director, 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges director C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina officer: Chief Medical Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David officer: Chief Product Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110